Compare Nuscale Power Corporation (SMR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Nuscale Power Corporation trades at $9.61 (market cap $4.06B), while State Street SPDR S&P Biotech ETF trades at $159.21. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| SMR | XBI | |
|---|---|---|
Market Cap | $4.06B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $53.43 | $164.28 |
52-Week Low | $7.59 | $86.92 |
Enterprise Value | $2.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NuScale Power (SMR) trades at $9.58, up 4.36% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net margin of -3,888.7%. Recent news highlights regulatory progress for its small modular reactors and potential from AI data center power demand, though revenue plunged 98.8% year-over-year in Q2 2026.
Outlook hinges on commercial deployment success, with a consensus price target of $10.50 offering 9.6% upside. High execution risk and cash burn are key concerns, but analyst sentiment is 50% buy-rated. Investors face volatility from project timelines versus speculative growth potential in nuclear energy.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
